150 related articles for article (PubMed ID: 11683633)
1. p22 is a novel plasminogen fragment with antiangiogenic activity.
Kwon M; Yoon CS; Fitzpatrick S; Kassam G; Graham KS; Young MK; Waisman DM
Biochemistry; 2001 Nov; 40(44):13246-53. PubMed ID: 11683633
[TBL] [Abstract][Full Text] [Related]
2. The tumor-suppressing activity of angiostatin protein resides within kringles 1 to 3.
MacDonald NJ; Murad AC; Fogler WE; Lu Y; Sim BK
Biochem Biophys Res Commun; 1999 Oct; 264(2):469-77. PubMed ID: 10529387
[TBL] [Abstract][Full Text] [Related]
3. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer.
Sim BK; O'Reilly MS; Liang H; Fortier AH; He W; Madsen JW; Lapcevich R; Nacy CA
Cancer Res; 1997 Apr; 57(7):1329-34. PubMed ID: 9102221
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human prothrombin kringles have potent anti-angiogenic activities and inhibit Lewis lung carcinoma tumor growth and metastases.
Kim TH; Kim E; Yoon D; Kim J; Rhim TY; Kim SS
Angiogenesis; 2002; 5(3):191-201. PubMed ID: 12831060
[TBL] [Abstract][Full Text] [Related]
5. Mutation of human plasminogen kringle 1-5 enhances anti-angiogenic action via increased interaction with integrin alpha(v)beta(3).
Chang PC; Chang YJ; Wu HL; Chang CW; Lin CI; Wang WC; Shi GY
Thromb Haemost; 2008 Apr; 99(4):729-38. PubMed ID: 18392331
[TBL] [Abstract][Full Text] [Related]
6. Disruption of interkringle disulfide bond of plasminogen kringle 1-3 changes the lysine binding capability of kringle 2, but not its antiangiogenic activity.
Lee H; Kim HK; Lee JH; You WK; Chung SI; Chang SI; Park MH; Hong YK; Joe YA
Arch Biochem Biophys; 2000 Mar; 375(2):359-63. PubMed ID: 10700393
[TBL] [Abstract][Full Text] [Related]
7. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells.
Cao Y; Ji RW; Davidson D; Schaller J; Marti D; Söhndel S; McCance SG; O'Reilly MS; Llinás M; Folkman J
J Biol Chem; 1996 Nov; 271(46):29461-7. PubMed ID: 8910613
[TBL] [Abstract][Full Text] [Related]
8. Characterization and biological activities of recombinant human plasminogen kringle 1-3 produced in Escherichia coli.
You WK; So SH; Sohn YD; Lee H; Park DH; Chung SI; Chung KH
Protein Expr Purif; 2004 Jul; 36(1):1-10. PubMed ID: 15177278
[TBL] [Abstract][Full Text] [Related]
9. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.
O'Reilly MS; Holmgren L; Shing Y; Chen C; Rosenthal RA; Moses M; Lane WS; Cao Y; Sage EH; Folkman J
Cell; 1994 Oct; 79(2):315-28. PubMed ID: 7525077
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition by kringle 5 of human plasminogen on endothelial cell migration, an important process in angiogenesis.
Ji WR; Barrientos LG; Llinás M; Gray H; Villarreal X; DeFord ME; Castellino FJ; Kramer RA; Trail PA
Biochem Biophys Res Commun; 1998 Jun; 247(2):414-9. PubMed ID: 9642142
[TBL] [Abstract][Full Text] [Related]
11. Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: possible biochemical mechanism of angiostatin's action.
Sharma MR; Rothman V; Tuszynski GP; Sharma MC
Exp Mol Pathol; 2006 Oct; 81(2):136-45. PubMed ID: 16643891
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic kringles derived from human plasminogen and apolipoprotein(a) inhibit fibrinolysis through a mechanism that requires a functional lysine-binding site.
Ahn JH; Lee HJ; Lee EK; Yu HK; Lee TH; Yoon Y; Kim SJ; Kim JS
Biol Chem; 2011 Apr; 392(4):347-56. PubMed ID: 21194375
[TBL] [Abstract][Full Text] [Related]
13. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth.
Cao Y; Chen A; An SS; Ji RW; Davidson D; Llinás M
J Biol Chem; 1997 Sep; 272(36):22924-8. PubMed ID: 9278456
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo antiangiogenic activity of a novel deca-peptide derived from human tissue-type plasminogen activator kringle 2.
Su L; Xu X; Zhao H; Gu Q; Zou H
Biochem Biophys Res Commun; 2010 Jun; 396(4):1012-7. PubMed ID: 20471363
[TBL] [Abstract][Full Text] [Related]
15. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.
Kuba K; Matsumoto K; Date K; Shimura H; Tanaka M; Nakamura T
Cancer Res; 2000 Dec; 60(23):6737-43. PubMed ID: 11118060
[TBL] [Abstract][Full Text] [Related]
16. Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils.
Scapini P; Nesi L; Morini M; Tanghetti E; Belleri M; Noonan D; Presta M; Albini A; Cassatella MA
J Immunol; 2002 Jun; 168(11):5798-804. PubMed ID: 12023382
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril.
Merchan JR; Chan B; Kale S; Schnipper LE; Sukhatme VP
J Natl Cancer Inst; 2003 Mar; 95(5):388-99. PubMed ID: 12618504
[TBL] [Abstract][Full Text] [Related]
18. Angiostatin and angiostatin-related proteins.
Soff GA
Cancer Metastasis Rev; 2000; 19(1-2):97-107. PubMed ID: 11191071
[TBL] [Abstract][Full Text] [Related]
19. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis.
Cao R; Wu HL; Veitonmäki N; Linden P; Farnebo J; Shi GY; Cao Y
Proc Natl Acad Sci U S A; 1999 May; 96(10):5728-33. PubMed ID: 10318952
[TBL] [Abstract][Full Text] [Related]
20. Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis.
Ji WR; Castellino FJ; Chang Y; Deford ME; Gray H; Villarreal X; Kondri ME; Marti DN; Llinás M; Schaller J; Kramer RA; Trail PA
FASEB J; 1998 Dec; 12(15):1731-8. PubMed ID: 9837863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]